Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time

Gastric cancer remains a major global health burden, ranking fifth in incidence worldwide and disproportionately affecting Asia, with China accounting for a significant share of cases and deaths. Early detection and minimally invasive treatment are critical to improving outcomes. Endoscopic submucosal dissection (ESD) is the preferred curative approach for early gastric cancer, enabling precise, en bloc tumor resection while preserving gastric function. However, ESD is technically complex, time-consuming, and associated with risks such as intraoperative and delayed bleeding and perforation. Th

Trial Details

NCT ID
NCT07401303
Phase
NA
Sponsor
Xijing Hospital of Digestive Diseases
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • ESD
Locations (sample)
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • scheduled to undergo ESD for an early gastric cancer (the indication for ESD under current guidelines)
  • both genders aged 18-75 years
  • no pretreatment (ESD, surgery, radiation therapy, or chemotherapy) performed on the stomach to be examined
  • platelet count of \>10×10\^9/L and hemoglobin count of \>8.0 g/L in blood tests performed in the 3 months before the ESD

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →